News
-
Absorption Systems Initiates Collaboration With Academic Researchers To Develop Improved In Vitro Pharmacokinetic Predictions
10/3/2011
In a collaborative effort, Absorption Systems is working with Drs. Ken Korzekwa and Swati Nagar of Temple University and Dr. Jeff Jones of Washington State University to develop technologies to improve the predictive power of certain in vitro-in vivo correlations (IVIVCs).
-
Quotient Announces Agreement With Phico Therapeutics And First Application Of RapidFACT For Nasal Delivery
9/14/2011
Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), recently announced an agreement with UK-based biotech, Phico Therapeutics (Phico).
-
Absorption Systems Boosts Ophthalmic Drug Testing
8/24/2011
Absorption Systems recently announced that, as part of the continuing expansion of capabilities at its San Diego, CA facility, the company has hired Glen Gum, M.S., Ph.D. as Associate Director of Preclinical Studies.
-
Cytokinetics Announces Phase I And Phase IIa Clinical Trial Results For Omecamtiv Mecarbil Published In The Journal Lancet
8/23/2011
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of results from two clinical trials of omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet.
-
GE Healthcare Launches Indicating FTA DMPK Cards For Colorless Biological Sample Bioanalysis
8/16/2011
GE Healthcare Life Sciences new Whatman Indicating FTA DMPK Cards enable simple and effective collection of colorless biosample fluids, such as plasma, urine and CSF, for use in pharmacokinetic and toxicokinetic studies.
-
Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With The U.S. National Cancer Institute
8/12/2011
Tekmira Pharmaceuticals Corporation a leading developer of RNA interference (RNAi) therapeutics, along with its collaborators at the United States National Cancer Institute (NCI), announced today that they have received approval from the United States Food and Drug Administration (FDA) to proceed with a new Phase 1 clinical trial for Tekmira's lead oncology product, TKM-PLK1.
-
Scientists Design Nano-Sized Drug Transporter To Fight Disease
7/29/2011
Scientists seeking to improve cancer treatments have created a tiny drug transporter that maximizes its ability to silence damaging genes by finding the equivalent of an expressway into a target cell.
-
PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
7/25/2011
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.
-
Data From Phase 1 Study Of NKTR-181 Demonstrate Proof-Of-Concept For Nektar's Novel Opioid Analgesic Candidate
6/7/2011
Nektar Therapeutics (NASDAQ: NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate.
This website uses cookies to ensure you get the best experience on our website. Learn more